- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05257590
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
A Phase 2, Open-Label Study of CVM-1118 in Combination With Nivolumab in Subjects With Unresectable Advanced Hepatocellular Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Nivolumab, a human IgG4 kappa monoclonal antibody acts as a checkpoint inhibitor, blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2 ) and therefore preventing the activation of T cells from attacking the cancer. Nivolumab is currently approved for several cancer types.
To meet the medical need, TaiRx, Inc. develops a new small molecule drug, CVM-1118 can promote apoptosis and delay proliferation. Moreover, CVM-1118 targets the formation of vasculogenic mimicry (VM). VM has been associated with tumor metastasis and poor clinical outcomes. VM is reported to be particularly active in tumor under hypoxia state when patients are treated with the potent vascular endothelial growth factor (VEGF) inhibitor like sorafenib or bevacizumab. Hence, the ability of inhibiting the VM network makes CVM-1118 a potential good combination drug with Nivolumab in advanced diseases such as hepatoma where Nivolumab alone has shown activity.
The safety profile of CVM-1118 dosing has been established in the phase 1 study. The analysis of metabolism pathways further showed that the potential drug-drug interactions of CVM-1118 and Nivolumab are very low.
Based on the mechanism of actions and the safety analysis of nivolumab and CVM-1118, the design of phase 2 trial with the combination therapy might have great potential for the patients with unresectable advanced HCC.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Yen-Ling Chen, PhD
- Phone Number: 113 886-2-2653-5007
- Email: yenlingchen@trx.com.tw
Study Locations
-
-
-
Kaohsiung, Taiwan
- Recruiting
- Kaohsiung Chang Gung Memorial Hospital
-
Contact:
- Sheng-Nan Lu, MD/Ph.D
-
Keelung, Taiwan
- Recruiting
- Keelung Chang Gung Memorial Hospital
-
Contact:
- Kun-Yun Yeh, MD/Ph.D
-
Tainan, Taiwan
- Recruiting
- National Cheng Kung University Hospital
-
Contact:
- Yan-Shen Shan, MD/PhD
-
Taipei, Taiwan, 100
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Pei-Jer Chen, MD/PhD
-
Taipei, Taiwan, 112
- Recruiting
- Taipei Veterans General Hospital
-
Contact:
- Yi-Hsiang Huang, MD/PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18+ (20+ for subjects in Taiwan)
Diagnosis of hepatocellular carcinoma
- Pathologically or cytologically-confirmed or clinically diagnosed in accordance with American Association for the Study of Liver Diseases (AASLD) criteria (i.e., radiologic imaging with cross-sectional multiphasic contrast CT or MRI showing a ≥ 1 cm liver lesion)
- Subjects with advanced-stage, unresectable hepatocellular carcinoma that is not appropriate for potentially curable therapy who have progressed from, been intolerant of prior systemic anti-cancer therapies (e.g., sorafenib, lenvatinib, atezolizumab in combination with bevacizumab).
- Barcelona Clinic Liver Cancer (BCLC) stage B not appropriate for or with disease progression after local regional therapy, or BCLC stage C
- Child-Pugh liver function class A
- Measurable disease (per mRECIST)
- ECOG performance status of 0 to 1
Adequate laboratory parameters including:
- AST and ALT ≤ 3.0 x ULN (≤ 5.0 x ULN if due to liver involvement)
- Total serum bilirubin ≤ 2.0 x ULN (≤ 3.0 x ULN for subjects with documented Gilbert's syndrome)
- ANC ≥1500/µL
- Platelets ≥ 90,000/µL
- HGB ≥ 9.0 g/dL
- Serum creatinine clearance of ≥ 50 mL/min based on Cockcroft-Gault formula
- Serum albumin ≥ 2.8 gm/dL
- INR ≤ 2.3
- PT/aPTT ≤ 1.2 x ULN
- QTcF ≤ 480 msec
Subjects are eligible to enroll if they have HBV-, or HCV-HCC, defined as follows:
- Chronic HBV infection as evidenced by detectable HBV DNA or HBsAg. Subjects with chronic HBV infection must be on antiviral therapy and have HBV DNA <500 IU/mL. If not on an antiviral therapy at screening, then subjects must be willing to start the antiviral therapy at the time of consent.
- Active or resolved HCV infection as evidenced by detectable HCV RNA or antibody.
Exclusion Criteria:
- HCC with portal vein invasion at the main portal branch (Vp4)
- Known history of esophageal varices or gastrointestinal bleeding within the past 3 months
- Prior immunotherapy for hepatoma
- ≤ 7 days from prior limited field palliative irradiation therapy and C1D1
- ≤ 28 days from prior irradiation therapy and C1D1
- ≤ 14 days (or 5 half-lives) from prior systemic anticancer therapy and C1D1
- ≤ 28 days from local regional therapy (e.g., trans-arterial embolization, radiofrequency ablation) and C1D1
- Presence of other active cancer(s) likely to require treatment in the next two (2) years or likely to impact the assessment of any study endpoints
- Active bacterial or fungal infection(s) requiring systemic therapy within 7 days prior to C1D1
- Known CNS metastases
- Known history of HIV infection
- Females who are currently pregnant or breast-feeding
- Known gastrointestinal disease that may significantly alter the absorption of oral medications
- Psychiatric illness or social situation that would interfere with compliance with study requirements
- History of clinically significant cardiovascular abnormalities
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nivolumab + CVM-1118
1 Cycle = 28 days Nivolumab, 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting from Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability. CVM-1118, 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects. Escalation of the starting dose will be dependent on the absence of Dose Limiting Toxicity in at least 7 of the initial 10 subjects treated at 200 mg, PO, BID. Individual subjects receiving a starting dose of 200 mg, PO, BID and who tolerate the initial 2 cycles with no more than Grade 2 related toxicity, will have the option of increasing their dose of CVM-1118 to 300 mg, PO, BID (600 mg total daily dose) starting with cycle 3 Tolerable dose of Nivolumab and CVM-1118 will be administered continuously for a 28-day cycle until progressive disease, unacceptable toxicity, or consent withdrawal. |
Nivolumab will be administered at 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting with Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability.
Other Names:
CVM-1118 will be administered 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)_mRECIST
Time Frame: 24 weeks after the last subject starts CVM-1118
|
Assessment by modified RECIST criteria
|
24 weeks after the last subject starts CVM-1118
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: 24 weeks after the last subject starts CVM-1118 and up to 1 year after the last-dose
|
Overall survival (OS) is defined as time from first dose of study drug to death
|
24 weeks after the last subject starts CVM-1118 and up to 1 year after the last-dose
|
Pharmacodynamics analysis for the relationship of Cmax and ORR
Time Frame: During Cycle 1 and Cycle 2 (each cycle is 28 days)
|
Relationship between Cmax and ORR will be evaluated
|
During Cycle 1 and Cycle 2 (each cycle is 28 days)
|
Pharmacodynamics analysis for the relationship of AUC and ORR
Time Frame: During Cycle 1 and Cycle 2 (each cycle is 28 days)
|
Relationship between AUC and ORR will be evaluated
|
During Cycle 1 and Cycle 2 (each cycle is 28 days)
|
Objective Response Rate (ORR)_RECIST v1.1
Time Frame: 24 weeks after the last subject starts CVM-1118
|
Assessment by RECIST v1.1 criteria
|
24 weeks after the last subject starts CVM-1118
|
Duration of response (DoR)
Time Frame: 24 weeks after the last subject starts CVM-1118 up to 1 year after the last-dose
|
Duration of response (DoR) is defined as time from the first documentation of response to the time of progression
|
24 weeks after the last subject starts CVM-1118 up to 1 year after the last-dose
|
Progression free survival (PFS)
Time Frame: 24 weeks after the last subject starts CVM-1118 up to 1 year after the last-dose
|
Progression free survival (PFS) is defined as time from the first dose of study drug to the time of progression or death
|
24 weeks after the last subject starts CVM-1118 up to 1 year after the last-dose
|
Time to progression (TTP)
Time Frame: 24 weeks after the last subject starts CVM-1118 up to 1 year after the last-dose
|
Time to progression (TTP) is defined as the time from the first dose of study drug to the time of progression
|
24 weeks after the last subject starts CVM-1118 up to 1 year after the last-dose
|
Disease control rate (DCR)
Time Frame: 24 weeks after the last subject starts CVM-1118 and up to 1 year after the last-dose
|
Disease control rate (DCR) is defined as the sum of complete response (CR), partial response (PR), and stable disease rate (SD)
|
24 weeks after the last subject starts CVM-1118 and up to 1 year after the last-dose
|
Rate of Adverse event (AE) and Serious Adverse Event (SAE)
Time Frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment by CTCAE v5.
|
Rate of Adverse event (AE) and Serious Adverse Event (SAE) are assessed using Common Terminology Criteria for Adverse Events v.5 (CTCAE) criteria
|
Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment by CTCAE v5.
|
Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ body temperature by CTCAE v5
Time Frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
|
Values with CTCAE v5 Grade ≧ 3 will be identified with flags.
A final outcome result with the number of participants with abnormal vital sign would be provided.
Normal ranges will also be provided.
|
Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
|
Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ blood pressure (both systolic and diastolic blood pressure) by CTCAE v5
Time Frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
|
Values with CTCAE v5 Grade ≧ 3 will be identified with flags.
A final outcome result with the number of participants with abnormal vital sign would be provided.
Normal ranges will also be provided.
|
Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
|
Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ Heart rate by CTCAE v5
Time Frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
|
Values with CTCAE v5 Grade ≧ 3 will be identified with flags.
A final outcome result with the number of participants with abnormal vital sign would be provided.
Normal ranges will also be provided.
|
Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
|
Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ respiratory rate by CTCAE v5
Time Frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
|
Values with CTCAE v5 Grade ≧ 3 will be identified with flags.
A final outcome result with the number of participants with abnormal vital sign would be provided.
Normal ranges will also be provided.
|
Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
|
Number of Participants With Abnormal baseline and out-of range Hematology Count by CTCAE v5
Time Frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
|
Values with CTCAE v5 Grade ≧ 3 will be identified with flags.
A final outcome result with the number of participants with abnormal laboratory values would be provided.
A list of all laboratory normal ranges will also be provided.
|
Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
|
Number of Participants With Abnormal Laboratory Values_Assessed the baseline and out-of range coagulation test by CTCAE v5
Time Frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
|
Values with CTCAE v5 Grade ≧ 3 will be identified with flags.
A final outcome result with the number of participants with abnormal laboratory values would be provided.
A list of all laboratory normal ranges will also be provided.
|
Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
|
Number of Participants With Abnormal Laboratory Values_Assessed the baseline and out-of range urinalysis test by CTCAE v5
Time Frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
|
Values with CTCAE v5 Grade ≧ 3 will be identified with flags.
A final outcome result with the number of participants with abnormal laboratory values would be provided.
A list of all laboratory normal ranges will also be provided.
|
Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
|
Number of patients with abnormalities in electrocardiography (ECG) reporting for PR, QRS, QT, and QTcF intervals
Time Frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
|
Values with CTCAE v5 Grade ≧ 3 will be identified with flags.
A final outcome result with the number of participants with abnormal laboratory values would be provided.
A list of all laboratory normal ranges will also be provided.
|
Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
|
Maximum Plasma Concentration [Cmax] of CVM-1118 and its metabolite CVM-1125 after CVM-1118 dosing
Time Frame: During Cycle 1 and Cycle 2 (each cycle is 28 days)
|
Maximum Plasma Concentration [Cmax] of CVM-1118 and its metabolite CVM-1125 will be measured to see maximum exposure after CVM-1118 dosing
|
During Cycle 1 and Cycle 2 (each cycle is 28 days)
|
Area Under the Curve [AUC] of CVM-1118 and its metabolite CVM-1125 after CVM-1118 dosing
Time Frame: During Cycle 1 and Cycle 2 (each cycle is 28 days)
|
Area Under the Curve [AUC] of CVM-1118 and its metabolite CVM-1125 after CVM-1118 dosing
|
During Cycle 1 and Cycle 2 (each cycle is 28 days)
|
Pharmacodynamics analysis for the relationship of Cmax and AE
Time Frame: During Cycle 1 and Cycle 2 (each cycle is 28 days)
|
Relationship between Cmax and AE will be evaluated
|
During Cycle 1 and Cycle 2 (each cycle is 28 days)
|
Pharmacodynamics analysis for the relationship of AUC and AE
Time Frame: During Cycle 1 and Cycle 2 (each cycle is 28 days)
|
Relationship between AUC and AE will be evaluated
|
During Cycle 1 and Cycle 2 (each cycle is 28 days)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Pei-Jer Chen, MD/PhD, National Taiwan University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Liver Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
Other Study ID Numbers
- CVM-008
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; American Society of Clinical Oncology; Radiological... and other collaboratorsWithdrawnHepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma AJCC v8 | Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Stage... and other conditionsUnited States
Clinical Trials on Nivolumab Injection [Opdivo]
-
University of California, San FranciscoBristol-Myers Squibb; National Cancer Institute (NCI)CompletedHIV/AIDS | Kaposi Sarcoma | ImmunosuppressionUnited States
-
Momotaro-Gene Inc.Baylor College of Medicine; Synteract, Inc.Active, not recruitingMalignant Pleural MesotheliomaUnited States
-
Tel-Aviv Sourasky Medical CenterRecruiting
-
Melbourne HealthActive, not recruitingHaematological MalignancyAustralia
-
Virogin Biotech Canada LtdRecruitingHepatocellular Carcinoma | Intrahepatic CholangiocarcinomaUnited States
-
Virogin Biotech Canada LtdRecruiting
-
Sarcoma Oncology Research Center, LLCAdvenchen Laboratories, LLCActive, not recruitingSoft Tissue Sarcoma | Small Cell Lung Cancer | Non Small Cell Lung Cancer | Solid Tumor, AdultUnited States
-
Assistance Publique - Hôpitaux de ParisBristol-Myers SquibbActive, not recruitingHepatocellular CarcinomaFrance
-
St. Petersburg State Pavlov Medical UniversityCompletedHodgkin LymphomaRussian Federation
-
Gruppo Oncologico del Nord-OvestCompletedSquamous Cell Carcinoma of Head and NeckItaly